NCT04412473
Unknown
Not Applicable
COVID-19 Respiratory Distress and Antithrombotic Drugs inSubject's Habits
University Hospital, Strasbourg, France1 site in 1 country1,000 target enrollmentApril 30, 2020
ConditionsSars-CoV2
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sars-CoV2
- Sponsor
- University Hospital, Strasbourg, France
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19
- Last Updated
- 5 years ago
Overview
Brief Summary
Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation. This evolution corresponds to an atypical acute respiratory distress syndrome (ARDS), the mechanism of which is poorly understood and difficult to predict. The general pathophysiology of ARDS, the vascular tropism of SARS-Cov2, the description of coagulopathy and numerous pulmonary artery thromboses in resuscitation and the encouraging investigation of antithrombotics in general ARDS
Investigators
Eligibility Criteria
Inclusion Criteria
- •Major Subject (≥18 years)
- •Subject hospitalised in HUS or GHRMSA for COVID-19
- •The diagnosis COVID-19 confirmed by smear or evoked by CT scan or chest X-ray without a differential diagnosis retained in the medical record
- •Subjects who, after being informed, do not wish to have their data reused for the purposes of this research
Exclusion Criteria
- •Subject who expressed opposition to participating in the study
- •Subject under guardianship or trusteeship
- •Subject under safeguard of justice
- •Patient hospitalized in a geriatric service or in a ward not labeled COVID (surgery, oncology,...) or in a short-term hospitalization unit without transfer to another service.
- •Serious patient on admission to the emergency room and recused from resuscitation.
Outcomes
Primary Outcomes
Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19
Time Frame: 1 month
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
Study Of Oxygen requirement in COVID-19 Patients in ICHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2022/01/039725il
Completed
Phase 4
Handling Oxygenation Targets in COVID-19Hypoxemic Respiratory FailureOxygen ToxicityNCT04425031Aalborg University Hospital726
Completed
Not Applicable
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress SyndromeSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)NCT04725084Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer355
Terminated
Not Applicable
AnaConDa-therapy in COVID-19 PatientsCOVID-19SARS CoV-2NCT05586126Jeroen Bosch Ziekenhuis42
Terminated
Phase 3
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)COVID-19NCT05605093University of Minnesota602